The Zhitong Finance App learned that BeiGene (06160) rose nearly 4% after the results. As of press release, it had risen 3.66% to HK$206.8, with a turnover of HK$362 million.
According to the news, on August 6, BeiGene announced its results for the second quarter of 2026, with total global revenue of about US$1.705 billion, up 30% year on year; GAAP net profit of about US$237 million, up 151% year on year; and adjusted net profit of about US$444 million, up 76% year on year.
Among them, product revenue for the second quarter of 2026 was US$1.7 billion, an increase of 29% over the previous year. Global sales of Baiyuze ® in the second quarter were US$1.2 billion, up 31% year over year; of these, in the US market, Baiyue® sales were US$893 million, up 31% year over year. Global sales of Baizean ® (tirelizumab) in the second quarter were US$229 million, an increase of 18% over the previous year. Global sales of Amgen's licensed products in the second quarter were US$157 million, up 25% year over year.
According to the Lyon Research Report, BeiGene has made further progress in the field of solid tumors. The GPC3 x 4-1BB bispecific antibody BGB-B2033 has completed a registered expansion study for later-line hepatocellular carcinoma in China, and plans to launch a global phase III clinical trial for second-line hepatocellular carcinoma in the second half of the year. Lyon said that the bank continues to be optimistic that the global commercialization of BeiGene is progressing well and that the new solid tumor pipeline is entering an advanced stage. In response to the increase in performance and guidelines, the 2026-2028 sales forecast will be raised by 4%, 3.3% and 3.2%, respectively, and the net profit forecast will increase by 23.5%, 12.5% and 7.3%, respectively.